Altimmune Q3 net loss $33.5M; pemvidutide shows liver fat reduction to undetectable levels

Altimmune, Inc.

2021-Q3 EPS reported -$1.79 revenue$1,132,698

Net loss of $33.5M ($0.81 per share) for Q3 2021, up from $17.8M in Q3 2020.
Cash and short-term investments totaled $199.9M at Sept 30, 2021; revenue fell to $0.2M from $2.9M.
Phase 1 pemvidutide data: mean weight loss up to 10.3% at 1.8 mg at week 12 without dose titration.
MRI-PDFF analysis in 5 subjects with hepatic steatosis showed liver fat fell to undetectable levels within 6 weeks (≥90% reduction).
Phase 2 obesity and NASH trials expected to start in 2022; IND for obesity by year-end 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.